COLUMBUS, Ohio--(BUSINESS WIRE)--Counsyl, a DNA testing and genetic counseling company, will present significant new research findings at the National Society of Genetic Counselors (NSGC) 36th Annual Conference this week at the Greater Columbus Convention Center in Columbus, Ohio.
Counsyl is committed to sharing data with the scientific and clinical community. Highlights from Counsyl on the NSGC scientific program include:
Lunch Seminar
“The First Trimester Genetic Risk Assessment: Methodology Matters”
12:15
- 1:30pm, Thursday, September 14, Short North Ballroom A & B
This seminar will cover various methodologies for carrier screening and non-invasive prenatal screening (NIPS) and how the differences can impact patient results. Speakers include:
- Dale Muzzey, PhD, director of scientific affairs, Counsyl
- Beth Denne, MS, CGC, director of genetic counseling services, Counsyl
- Sarah Hash, MS, CGC, Maternal-Fetal Medicine Associates of Maryland
Educational Breakouts
“Is More Better? A Debate on Carrier Screening for the Next
Generation”
10:30am, Friday, September 15
Expanded carrier screening -- which involves screening for a broader set of hereditary conditions in the general population -- is growing in practice. This breakout session will feature expert commentary on the clinical value of expanded carrier screening from Gabriel Lazarin, MS, CGC, vice president of medical affairs, Counsyl.
“Into the Weeds of NIPT: a Survey of Algorithms for Analysis of
Aneuploidies, Fetal Fraction, and Microdeletions”
10:10am,
Saturday, September 16
This educational breakout session featuring expert commentary from Dale Muzzey, PhD, will discuss the two most common non-invasive prenatal screening platforms.
Platform Presentations
| Platform | Full Title | Time, Date | |||
| 1208 | Software-assisted manual review of NGS results as an alternative to routine Sanger sequencing confirmation | 3:45pm, 9/15 | |||
| 1367 | NIPS for high BMI patients: evaluating the impact of deep whole genome sequencing | 11:45am, 9/16 | |||
| 1213 | Counseling experience with incidental cancer genes in expanded carrier screening | 12:00pm, 9/16 | |||
Prenatal / Pediatric Research
| Poster | Full Title | Time, Date | Primary Author | ||||
| B-224 | Strategies to avoid false positives caused by maternal copy number variants in non-invasive prenatal screening | 5:45pm, 9/14 | K. Kaseniit | ||||
| C-219 | Copy number variant calling on a 177-gene expanded carrier screening panel | 1:15pm, 9/15 | K. Beauchamp | ||||
| C-228 | The frequency and impact of dependent alleles in expanded carrier screening | 1:15pm, 9/15 | L. Cushman Spock | ||||
Cancer Research
| Poster | Full Title | Time, Date |
Primary Author |
|||
| A-100 | Incidental detection of colon cancer via non-invasive prenatal screening and comparative re-screen after treatment | 5:15pm, 9/13 | S. Hancock | |||
| B-86 | Variants that cross the line: an internal review of classification evidence for truncations of the C-terminus | 5:45pm, 9/14 | M. Judkins | |||
Access / Service Delivery Research
| Poster | Full Title | Time, Date | Primary Author | |||
| A-22 | A pilot study of patient experience with an automated assessment tool for hereditary cancer risk | 5:15pm, 9/13 | J. Lim-Harashima | |||
| B-8 | Next-generation counseling: a model for non-invasive prenatal screening results disclosure and patient management | 5:45pm, 9/14 | C. Schmitt | |||
| C-27 | Comparison and concordance of reported cancer family history between an automated patient assessment tool and genetic counselor recorded pedigrees: findings from a pilot study | 1:15pm, 9/15 | L. Bucheit | |||
Counsyl will also be exhibiting at booth #113 from Wednesday, September 13 to Friday, September 15. Visitors to the booth will have the opportunity to receive a professional portrait at Counsyl’s headshot lounge.
Visitors are also invited to learn more about Counsyl Complete, the service platform that enhances practice workflow across Counsyl’s full range of genetic screening offerings:
- Foresight™ Carrier Screen: Identifies carrier status of couples to determine risk of passing down serious inherited health conditions to children. Counsyl is the pioneer and U.S. market leader in expanded carrier screening, and recently introduced an updated version of this test, which now improves our industry-leading rate of detecting affected pregnancies by 16% to 1:42.
- Prelude™ Prenatal Screen: Detects, as early as the tenth week of pregnancy, if a baby has an increased chance for chromosome conditions such as Down syndrome, and can reduce the need for invasive tests like amniocentesis. With the lowest (0.1%) “no-call” rate among available non-invasive prenatal screening tests, Prelude helps providers deliver actionable insights to more patients.
- Reliant™ Cancer Screen: Examines up to 36 different genes associated with an increased risk of 10 cancers (including breast, ovarian, pancreatic and others). Reliant helps women’s health providers and their patients get ahead of cancer by focusing on genes with clear cancer risks and actionable patient management guidelines.
Counsyl is proud to be a Bronze Sponsor of this year’s NSGC conference, which focuses on the latest information and educational materials for genetic counselors. Counsyl employs more than 50 board-certified genetic counselors and has delivered more than 60,000 genetic counseling sessions.
About Counsyl
Counsyl is a DNA testing and genetic counseling company committed to helping patients understand their DNA and how it can inform important health decisions. Whether it’s starting a family or evaluating risk for cancer, Counsyl's DNA tests provide patients with early awareness about genetic conditions, so they can live informed and prepare for the future. Counsyl has screened more than 750,000 patients and served more than 10,000 healthcare professionals. For more information, visit www.counsyl.com. Sign up for news announcements from Counsyl at subscribe.counsyl.com.
